
Zelira Therapeutics Ltd’s (OTCQB:ZLDAF) (ASX:ZLD) insomnia medication Zenivol has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market.
According to the company, Zenivol is the world's first and only clinically validated, pharmaceutical-grade, cannabis-based sleep medication. Zenivol's clinical research was peer reviewed in the Journal of Sleep. It is currently available by prescription in Australia under the country's legal cannabis regulations.